Agilent Technologies Inc. has acquired Avida Biomed. The acquisition augments Agilent’s strategy to expand into the high-growth clinical research and diagnostics markets. Terms of the deal were not disclosed.
Agilent provides bio-analytical solutions and services to the life sciences, diagnostics and genomics, chemical analysis, communications and electronics industries worldwide. Its global headquarters is in Santa Clara, California. Agilent was established in 1999 as a spin-off from Hewlett-Packard.
Fremont, California-based Avida Biomed is an early-stage life sciences company that develops target enrichment workflows with capabilities for clinical researchers utilizing next-generation sequencing approaches to study cancer.
According to data captured in the LevinPro HC database, this is the second Biotechnology transaction of 2023. There were 141 Biotechnology deals reported in 2022.
